Evicenter
MarkdownMedical informationP&T meetings
Claseprubart (DNTH103)

Chronic inflammatory demyelinating polyneuropathy

Launch
Not announced
Last updated
143 sources

Section 4 of 6

Clinical evidence

126 evidence topics · 34 sources

Study summaries

CAPTIVATE

Objective
Location and study date
Study locations by country in the ClinicalTrials.gov record
CountryLocations listed in the record
United States“Birmingham, Alabama, United States, 35294”; “Phoenix, Arizona, United States, 85028”; “Scottsdale, Arizona, United States, 85251'”; “Los Angeles, California, United States, 90048”; “San Francisco, California, United States, 94109”; “San Francisco, California, United States, 94158”; “New Haven, Connecticut, United States, 06520”; “Washington D.C., District of Columbia, United States, 20007”; “Maitland, Florida, United States, 32751”; “Tampa, Florida, United States, 33620”; “Honolulu, Hawaii, United States, 96817”; “Chicago, Illinois, United States, 60611”; “Edwardsville, Illinois, United States, 62025”; “Indianapolis, Indiana, United States, 46202”; “Kansas City, Kansas, United States, 66160”; “Burlington, Massachusetts, United States, 01805”; “East Lansing, Michigan, United States, 48824”; “Omaha, Nebraska, United States, 68198”; “Lebanon, New Hampshire, United States, 03766”; “New York, New York, United States, 10021”; “New York, New York, United States, 10032”; “Cincinnati, Ohio, United States, 45219”; “Columbus, Ohio, United States, 43221”; “Portland, Oregon, United States, 97239”; “Nashville, Tennessee, United States, 37232”; “Dallas, Texas, United States, 75243”; “Denton, Texas, United States, 76208”; “Houston, Texas, United States, 77030”; “Houston, Texas, United States, 77054”; “Round Rock, Texas, United States, 78681”; “Sugar Land, Texas, United States, 77478”; “Seattle, Washington, United States, 98195”
Argentina“Buenos Aires, Buenos Aires, Argentina”; “Rosario, Santa Fe Province, Argentina”; “Buenos Aires, Argentina”; “San Miguel de Tucumán, Argentina”
Australia“Liverpool, New South Wales, Australia”; “Randwick, New South Wales, Australia, 2031”; “Saint Leonards, New South Wales, Australia, 2065”; “Sydney, New South Wales, Australia, 2033”; “Southport, Queensland, Australia, 4215”; “Melbourne, Victoria, Australia, 3004”
Belgium“Anderlecht, Brussels Capital, Belgium”; “Brussels, Belgium”
Brazil“Rio de Janeiro, Rio de Janeiro, Brazil, 20551-030”; “Campinas, São Paulo, Brazil”; “Belo Horizonte, Brazil, 30130-100”; “Natal, Brazil”; “Porto Alegre, Brazil, 90610-000”; “Salvador, Brazil, 40290-000”; “São Paulo, Brazil, 04038”; “São Paulo, Brazil, 05403-000”; “São Paulo, Brazil”
Bulgaria“Sofia, Bulgaria”
China“Hefei, Anhui, China, 230001”; “Guangzhou, Guangdong, China, 510080”; “Changsha, Hu'Nan, China, 410008”; “Changsha, Hu'Nan, China, 410013”; “Chifeng, Inner Mongolia, China, 024050”; “Suzhou, Jiangsu, China, 215006”; “Beijing, China, 100034”; “Beijing, China, 100191”; “Chengdu, China, 610072”; “Fujian, China, 350001”; “Guangdong, China, 510180”; “Guangzhou, China, 510515”; “Jilin City, China, 130021”; “Shanghai, China, 200031”; “Shanghai, China, 200040”; “Sichuan, China, 610072”; “Taiyuan, China”; “Wuhan, China”
Colombia“Medellín, Antioquia, Colombia”; “Antioquia, Colombia”; “Medellín, Colombia”
Croatia“Osijek, Croatia”
Denmark“Aarhus, Denmark, 8200”; “Copenhagen, Denmark”
Eswatini“Ulm, Eswatini, 89081”
France“Bordeaux, France, 33000”; “Brest, France, 29200”; “Bron, France, 69500”; “Clermont-Ferrand, France, 63000”; “Libourne, France, 33500”; “Marseille, France, 13005”; “Nice, France, 06000”; “Paris, France, 75013”; “Paris, France, 75610”; “Strasbourg, France, 67200”; “Tours, France, 37000”
Georgia“Tbilisi, Georgia”
Germany“München, Bavaria, Germany”; “Sande, Lower Saxony, Germany, 26452”; “Aachen, Germany, 52074”; “Greifswald, Germany, 17489”; “Rüdersdorf, Germany, 15562”; “Sande, Germany, 26452”
Israel“Beersheba, Israel”; “Haifa, Israel, 3109601”; “Safed, Israel”
Italy“Bergamo, Italy, 24127”; “Bologna, Italy, 40139”; “Genova, Italy, 16132”; “Gussago, Italy, 25064”; “Milan, Italy, 20126”; “Milan, Italy, 20132”; “Milan, Italy”; “Modena, Italy”; “Monza, Italy, 20900”; “Pavia, Italy, 27100”; “Ponderano, Italy, 13875”; “Roma, Italy, 00128”; “Roma, Italy, 00133”; “Roma, Italy, 00189”; “Roma, Italy”; “Salerno, Italy, 84131”; “Terni, Italy”
Japan“Niigata, Chubu, Japan”; “Kawasaki, Kanto, Japan”; “Tsukuba, Kanto, Japan”; “Kurashiki, Okayama-ken, Japan, 701-0192”; “Hirakata, Osaka, Japan”; “Kawagoe, Saitama, Japan”; “Ube, Yamaguchi, Japan, 755-0046”; “Chiba, Japan, 260-8677”; “Kyoto, Japan, 606-8507”; “Nagoya, Japan, 466-8560”; “Sapporo, Japan, 060-8556”; “Tokyo, Japan, 152-8550”; “Tokyo, Japan”
Latvia“Riga, Latvia, LV-1002”; “Riga, Latvia, LV-1024”
Malaysia“Kota Kinabalu, Sabah, Malaysia”; “Serdang, Salangor, Malaysia”; “Kuching, Sarawak, Malaysia”; “George Town, Malaysia, 11700”; “Johor Bahru, Malaysia, 80100”; “Kota Kinabalu, Malaysia”; “Kuala Lumpur, Malaysia, 50586”; “Kuala Lumpur, Malaysia, 50603”; “Kuala Lumpur, Malaysia, 56000”; “Kuching, Malaysia”; “Serdang, Malaysia, 43400”; “Sungai Buloh, Malaysia”
Netherlands“Amsterdam, Netherlands”; “Utrecht, Netherlands”
North Macedonia“Skopje, North Macedonia, 1000”
Philippines“Batangas, Philippines”; “Cebu City, Philippines”; “City of Muntinlupa, Philippines”; “Iloilo City, Philippines”
Poland“Bydgoszcz, Poland, 85-090”; “Krakow, Poland, 30-688”; “Lodz, Poland, 90-324”; “Lublin, Poland, 20-701”; “Lublin, Poland, 20-718”; “Lublin, Poland, 7763138”; “Warsaw, Poland, 04-141”; “Wroclaw, Poland, 50-367”
Romania“Bucharest, Romania, 050474”; “Târgu Mureş, Romania, 540136”
Serbia“Belgrade, Serbia, 11000”; “Kragujevac, Serbia, 34000”; “Niš, Serbia, 18000”
South Korea“Daegu, South Korea”; “Daejeon, South Korea”; “Seoul, South Korea”; “Uijeongbu-si, South Korea”; “Yangsan, South Korea”
Spain“Barcelona, Barcelona, Spain, 08916”; “Alicante, Spain, 03010”; “Barcelona, Spain, 08025”; “Barcelona, Spain, 08041”; “Bilbao, Spain, 48013”
Thailand“Bangkok, Thailand, 10400”; “Bangkok, Thailand”; “Chiang Mai, Thailand, 50200”; “Hat Yai, Thailand”; “Khlong Luang, Thailand”; “Khon Kaen, Thailand, 40002”; “Khon Kaen, Thailand”
Turkey (Türkiye)“Ankara, Turkey (Türkiye), 06230”; “Bursa, Turkey (Türkiye)”; “Istanbul, Turkey (Türkiye)”; “Samsun, Turkey (Türkiye)”; “Zeytinburnu, Turkey (Türkiye), 34010”
United Kingdom“Manchester, England, United Kingdom”; “Oxford, United Kingdom”
Vietnam“Hanoi, Vietnam”
Study design
Eligibility criteria
Treatment
Intravenous loading dose amount

No evidence found.

Study outcomes
Rationale for using adjusted INCAT disability score relapse as the primary endpoint
Secondary outcomes in the ClinicalTrials.gov record

“Part B: Time to Decrease of ≥ 4 Points (Centile Metric) in Inflammatory Rasch-built Overall Disability Scale (I-RODS) Score” (opens the source at this quote in a new tab)

“The I-RODS score ranges from 0-100, with lower scores indicating the greatest degree of disability.” (opens the source at this quote in a new tab)

“Part B: Time to Decrease of ≥ 8 kilopascal (kPa) in Grip Strength in the Dominant Hand” (opens the source at this quote in a new tab)

“This is measured with a handheld device called a vigorimeter.” (opens the source at this quote in a new tab)

“Part B: Percentage of Participants who Relapse as Assessed by the Adjusted INCAT” (opens the source at this quote in a new tab)

“Part A: Percentage of Participants with a Confirmed Response to DNTH103 as Assessed by the Adjusted INCAT” (opens the source at this quote in a new tab)

“Parts A and B: Change in Medical Research Council Sum Score (MRC-SS)” (opens the source at this quote in a new tab)

“Parts A and B: Change in Euro-Quality of Life Visual Analogue Scale (EQ-VAS)” (opens the source at this quote in a new tab)

“Parts A and B: Change in Fatigue Severity Scale (FSS)” (opens the source at this quote in a new tab)

“Parts A, B, OLE, and Safety Follow-up: Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (SAEs)” (opens the source at this quote in a new tab)

“Parts A, B, OLE, and Safety Follow-up: Serum Concentrations of DNTH103” (opens the source at this quote in a new tab)

“Parts A, B, and OLE: Change from Baseline in Complement Total Blood Test (CH50)” (opens the source at this quote in a new tab)

“Parts A, B, OLE, and Safety Follow-up: Incidence and Titer of Antidrug Antibodies (ADAs)” (opens the source at this quote in a new tab)

Grip strength secondary endpoint: Vigorimeter validity and the 8 kPa threshold
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size calculation for Part B

No evidence found.

Description of analysis sets
Part B analysis populations

No evidence found.

Results
Participant disposition
Enrollment and randomization to Part B to date

No evidence found.

Baseline characteristics
Baseline demographics and disease characteristics of the interim analysis set
CharacteristicClaseprubart 300 mg every 2 weeks (N=40)
Age, years, mean (SD)“56.9 (12.5)”
Age, years, median (range)“59.5 (31–74)”
Male, n (%)“26 (65.0)”
Typical CIDP, n (%)“35 (87.5)”
Multifocal CIDP, n (%)“2 (5.0)”
Motor CIDP, n (%)“3 (7.5)”
Mean time since diagnosis, years (SD)“4.2 (6.1)”
Prior treatment: SoC-treated, n (%)“27 (67.5)”
Prior treatment: immunoglobulin, n (%)“19 (47.5)”
Prior treatment: oral corticosteroids, n (%)“8 (20.0)”
Prior treatment: SoC-refractory, n (%)“9 (22.5)”
Prior treatment: treatment-naive, n (%)“4 (10.0)”
INCAT, mean (SD)“4.0 (1.21)”
Grip strength, kPa, mean (SD)“41.4 (20.0)”
I-RODS, mean (SD)“47.9 (13.7)”
MRC-SS, mean (SD)“50.5 (5.6)”
Race, ethnicity, and enrollment by region

No evidence found.

Efficacy results
Change from Part A baseline at the last evaluable visit, by responder status
Measure, mean (SD)Confirmed responders (n=30)Non-responders (n=10)
INCAT (decrease is improvement)“–1.6 (0.89)”“0.7 (1.06)”
Grip strength (increase is improvement)“15.9 (12.78)”“–7.5 (12.19)”
MRC-SS (increase is improvement)“5.1 (3.93)”“–2.3 (8.82)”
I-RODS (increase is improvement)“8.9 (12.08)”“–3.0 (10.69)”
Response by prior treatment group

No evidence found.

Part B time to relapse

No evidence found.

Health-related quality of life and patient-reported outcomes
Inflammatory Rasch-built Overall Disability Scale change from Part A baseline
Measure, mean (SD)Confirmed responders (n=30)Non-responders (n=10)
I-RODS (increase is improvement)“8.9 (12.08)”“–3.0 (10.69)”
EQ-VAS and Fatigue Severity Scale results

No evidence found.

Safety results
Adverse events in the interim analysis set
Event, n (%)Claseprubart 300 mg every 2 weeks (N=40)
Patients with any AEs“24 (60)”
Grade 3 (not treatment-related)“1 (3)”
Treatment-related infections“0 (0)”
Patients with any SAEs“1 (3)”
Treatment-related SAEs“0 (0)”
Serious infections“0 (0)”
AE leading to discontinuation“0 (0)”
Adverse events by type

No evidence found.

Study limitations
Summary

The only CAPTIVATE results are from an interim analysis of open-label Part A: of the first 40 participants who completed Part A with evaluable efficacy data, 30 (75%) were confirmed responders in this per-protocol interim analysis, and the company describes the summaries as preliminary. Part A has no comparator arm, so the 75% response rate and the changes in grip strength, MRC-SS, and I-RODS among responders are uncontrolled. In the randomized-withdrawal design, only Part A responders enter the placebo-controlled Part B, whose primary endpoint is time to relapse (an increase of at least 1 point in adjusted INCAT); Part B results are expected by the end of 2028 and will describe participants who first responded to claseprubart. The trial was resized after the interim analysis: in March 2026 the company announced plans, pending regulatory approval, to remove the 600 mg Part B arm and to enroll up to 256 participants in Part A (previously up to 480) to randomize 128 in Part B (previously 192); the investigators later described 1:1 randomization in Part B to claseprubart 300 mg or placebo, and in November 2026 Part A was projected to require fewer than 200 participants, while the registry still lists an estimated enrollment of 256.

DNTH103-AU-001

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics

No evidence found.

Efficacy results
Part C pharmacokinetics after immunoglobulin G

No evidence found.

Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Part C safety

No evidence found.

Study limitations
Summary

DNTH103-AU-001 enrolled healthy adults aged 18 to 65 years and excluded people with a history of autoimmune disease, so its safety, pharmacokinetic, and pharmacodynamic findings come from a population without the diseases claseprubart is being developed to treat, and the company states that the same results may not be seen in patients in later trials. Each dose cohort was planned with 8 participants (6 receiving DNTH103 and 2 receiving placebo); the company's top-line announcement reported 52 healthy volunteers in 7 single and multiple ascending dose cohorts, and later company documents reported 60 healthy volunteers in 8 cohorts who completed dosing as of December 2023, while the registry records a final accrual of 68 for Parts A and B and 9 for the open-label, uncontrolled Part C. The Parts A and B registry record lists recruitment in Christchurch, New Zealand, the company states that the phase 1 trial was conducted in New Zealand, and both registry records state that no documents have been uploaded by study researchers, so the available results come from company press releases, presentations, and annual reports, and no Part C result has been reported. The company states that FDA acceptance of data from trials conducted outside the United States is subject to conditions the FDA imposes.